We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Omega Diagnostics Group Plc | LSE:ODX | London | Ordinary Share | GB00B1VCP282 | ORD 4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.20 | 2.00 | 2.40 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMODX
RNS Number : 9407U
Omega Diagnostics Group PLC
18 July 2018
Omega Diagnostics Group PLC
("Omega" or "the Company")
VISITECT(R) CD4 commercialisation update
Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the following update on its VISITECT(R) CD4 commercialisation programme.
The Company announces the appointment of three new dedicated distributors in Ghana, Zambia and Zimbabwe. This follows on from the appointment of their first dedicated distributor for CD4 in Nigeria. All three countries require product registration, which has also commenced. Once completed, this will allow business to business sales to commence through the Company's distributors. The three countries have a high prevalence of people living with HIV and have been priortised on that basis.
Colin King, CEO of Omega commented: "I am pleased to see our commercialisation plan for CD4 taking shape as this is key part of our strategy to delivering shareholder value. This also provides further evidence that our CD4 test (the world's first true point-of-care test) will make a significant difference to people living with HIV in resource-poor environments."
The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.
Contacts:
Omega Diagnostics Group PLC Tel: 01259 763 030 Colin King, Chief Executive www.omegadiagnostics.com Kieron Harbinson, Group Finance Director finnCap Ltd Tel: 020 7220 0500 Geoff Nash/James Thompson (Corporate Finance) Camille Gochez/ Abigail Wayne (Corporate Broking) Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com Paul McManus Mob: 07980 541 893 Lianne Cawthorne Mob: 07584 391 303
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
UPDEASXXFLFPEFF
(END) Dow Jones Newswires
July 18, 2018 02:00 ET (06:00 GMT)
1 Year Omega Diagnostics Chart |
1 Month Omega Diagnostics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions